Literature DB >> 18307754

Selection of patients for surgery for primary aldosteronism.

Pierre-François Plouin1, Patrick Rossignol, Laurence Amar.   

Abstract

1. Primary aldosteronism is a condition characterized by renin suppression and various degrees of hypertension and hypokalemia caused by aldosterone hypersecretion. 2. The adoption of the aldosterone-to-renin ratio determination as a screening test has led to an increase in the prevalence of diagnosed cases of primary aldosteronism. 3. Primary aldosteronism is confirmed by the demonstration of either sustained absolute aldosterone hypersecretion, or non-suppressible aldosterone hypersecretion. 4. Computed tomography and adrenal vein sampling can then be used to distinguish between idiopathic primary aldosteronism and the surgically remediable forms: aldosterone-producing adenoma and primary adrenal hyperplasia. 5. In patients with aldosterone-producing adenoma or primary adrenal hyperplasia, unilateral adrenalectomy generally results in the normalization of aldosterone secretion and kalemia, but normotension is achieved in only half of the cases. Nevertheless, in many cases without hypertension cure, adrenalectomy leads to an improvement in hypertension control with lower blood pressure levels and/or less antihypertensive medication.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18307754     DOI: 10.1111/j.1440-1681.2008.04909.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  1 in total

1.  Comprehensive re-sequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the KCNJ5 potassium channel selectivity filter.

Authors:  Tobias Åkerström; Joakim Crona; Alberto Delgado Verdugo; Lee F Starker; Kenko Cupisti; Holger S Willenberg; Wolfram T Knoefel; Wolfgang Saeger; Alfred Feller; Julian Ip; Patsy Soon; Martin Anlauf; Pier F Alesina; Kurt W Schmid; Myriam Decaussin; Pierre Levillain; Bo Wängberg; Jean-Louis Peix; Bruce Robinson; Jan Zedenius; Martin Bäckdahl; Stefano Caramuta; K Alexander Iwen; Johan Botling; Peter Stålberg; Jean-Louis Kraimps; Henning Dralle; Per Hellman; Stan Sidhu; Gunnar Westin; Hendrik Lehnert; Martin K Walz; Göran Åkerström; Tobias Carling; Murim Choi; Richard P Lifton; Peyman Björklund
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.